Aldeyra Therapeutics enrolls first patient in Phase 2b Clinical Trial for DED

Clinical-stage biotechnology company,devoted to treating inflammation and inborn errors of metabolism, Aldeyra Therapeutics enrolled first patient in a Phase 2b Clinical Trial of topical ocular reproxalap for the treatment of dry eye disease (DED). The Phase 2b Clinical trial will test two concentrations of topical reproxalap (0.1% and 0.25%) against vehicle over 12 weeks of treatment in 300 patients with moderate dry eye disease.

Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra said “Based on the positive results from the Phase 2a dry eye disease clinical trial with our topical ocular product candidate reproxalap announced in September 2017, we are pleased to begin enrolling our Phase 2b clinical trial, and expect to report results in the second half of this year.”

Aldeyra’s aldehyde trap platform sequester generated Reproxalap and other product candidates to further the degradation of  pro-inflammatory aldehyde mediators, a class of small molecule therapeutic targets that are elevated in DED patients.